Você procurou por: retroviiruseravimitega (Estoniano - Inglês)

täiskasvanutel vähendas edurant koos teiste retroviiruseravimitega vere hiv-1 sisaldust sama efektiivselt kui võrdlusravim.
in adults, edurant in combination with other antiretroviral medicines was as effective as the comparator medicine at reducing the level of hiv-1 in the patients’ blood.

inimravimite komitee jõudis otsusele, et epiviri kasulikkus hiv- nakkusega täiskasvanute ja laste ravis koos teiste retroviiruseravimitega on suurem kui sellega kaasnevad riskid.
the committee for medicinal products for human use (chmp) decided that epivir’ s benefits are greater than its risks in combination with other antiretroviral medicinal products for the treatment of hiv infected adults and children.

inimravimite komitee otsustas, et viracepti kasulikkus selle kasutamisel hiv- 1 nakkusega täiskasvanutel, noorukitel ja vähemalt kolmeaastastel lastel koos teiste retroviiruseravimitega on suurem kui sellega kaasnevad riskid.
the committee for medicinal products for human use (chmp) decided that viracept’ s benefits are greater than its risks in antiretroviral combination treatment of hiv-1 infected adults, adolescents and children of three years of age and older.

inimravimite komitee jõudis otsusele, et fuzeoni kasulikkus kombinatsioonis teiste retroviiruseravimitega hiv-1-nakkusega patsientide ravis, kelle puhul on varasem ravi vähemalt ühe ravimiga igast järgnevast retroviiruseravimi klassist – proteaasiinhibiitorid, mittenukleosiid- pöördtranskriptaasi inhibiitorid ja nukleosiid-pöördtranskriptaasi inhibiitorid – osutunud ebaefektiivseks või kes ei talunud varasemat ravi retroviiruseravimitega, on suurem kui sellega kaasnevad riskid.
the committee for medicinal products for human use (chmp) decided that fuzeon’s benefits are greater than its risks in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following classes, protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens.